Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.
Saved in:
| Title: | Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. |
|---|---|
| Authors: | Harter, P.1,2 (AUTHOR) P.Harter@kem-med.com, Trillsch, F.2,3 (AUTHOR), Okamoto, A.4,5 (AUTHOR), Reuss, A.6,7 (AUTHOR), Kim, J.-W.8,9 (AUTHOR), Rubio-Pérez, M.J.10,11 (AUTHOR), Vardar, M.A.12,13,14 (AUTHOR), Scambia, G.15,16 (AUTHOR), Trédan, O.17,18 (AUTHOR), Nyvang, G.-B.19,20 (AUTHOR), Colombo, N.21,22 (AUTHOR), Bidziński, M.23,24 (AUTHOR), Grimm, C.25,26 (AUTHOR), Lheureux, S.27,28 (AUTHOR), Van Nieuwenhuysen, E.29,30 (AUTHOR), Heitz, F.2,31,32 (AUTHOR), Wenham, R.M.33,34 (AUTHOR), Nishio, S.5,35 (AUTHOR), Lim, M.C.9,36 (AUTHOR), Marquina, G.11,37 (AUTHOR) |
| Source: | Annals of Oncology. Apr2026, Vol. 37 Issue 4, p503-520. 18p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 192379864 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Harter%2C+P%2E%22">Harter, P.</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<i> P.Harter@kem-med.com</i><br /><searchLink fieldCode="AR" term="%22Trillsch%2C+F%2E%22">Trillsch, F.</searchLink><relatesTo>2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Okamoto%2C+A%2E%22">Okamoto, A.</searchLink><relatesTo>4,5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Reuss%2C+A%2E%22">Reuss, A.</searchLink><relatesTo>6,7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kim%2C+J%2E-W%2E%22">Kim, J.-W.</searchLink><relatesTo>8,9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rubio-Pérez%2C+M%2EJ%2E%22">Rubio-Pérez, M.J.</searchLink><relatesTo>10,11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vardar%2C+M%2EA%2E%22">Vardar, M.A.</searchLink><relatesTo>12,13,14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Scambia%2C+G%2E%22">Scambia, G.</searchLink><relatesTo>15,16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Trédan%2C+O%2E%22">Trédan, O.</searchLink><relatesTo>17,18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nyvang%2C+G%2E-B%2E%22">Nyvang, G.-B.</searchLink><relatesTo>19,20</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Colombo%2C+N%2E%22">Colombo, N.</searchLink><relatesTo>21,22</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bidziński%2C+M%2E%22">Bidziński, M.</searchLink><relatesTo>23,24</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Grimm%2C+C%2E%22">Grimm, C.</searchLink><relatesTo>25,26</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lheureux%2C+S%2E%22">Lheureux, S.</searchLink><relatesTo>27,28</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Van+Nieuwenhuysen%2C+E%2E%22">Van Nieuwenhuysen, E.</searchLink><relatesTo>29,30</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Heitz%2C+F%2E%22">Heitz, F.</searchLink><relatesTo>2,31,32</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wenham%2C+R%2EM%2E%22">Wenham, R.M.</searchLink><relatesTo>33,34</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nishio%2C+S%2E%22">Nishio, S.</searchLink><relatesTo>5,35</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lim%2C+M%2EC%2E%22">Lim, M.C.</searchLink><relatesTo>9,36</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Marquina%2C+G%2E%22">Marquina, G.</searchLink><relatesTo>11,37</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. Apr2026, Vol. 37 Issue 4, p503-520. 18p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=192379864 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.11.020 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 18 StartPage: 503 Titles: – TitleFull: Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Harter, P. – PersonEntity: Name: NameFull: Trillsch, F. – PersonEntity: Name: NameFull: Okamoto, A. – PersonEntity: Name: NameFull: Reuss, A. – PersonEntity: Name: NameFull: Kim, J.-W. – PersonEntity: Name: NameFull: Rubio-Pérez, M.J. – PersonEntity: Name: NameFull: Vardar, M.A. – PersonEntity: Name: NameFull: Scambia, G. – PersonEntity: Name: NameFull: Trédan, O. – PersonEntity: Name: NameFull: Nyvang, G.-B. – PersonEntity: Name: NameFull: Colombo, N. – PersonEntity: Name: NameFull: Bidziński, M. – PersonEntity: Name: NameFull: Grimm, C. – PersonEntity: Name: NameFull: Lheureux, S. – PersonEntity: Name: NameFull: Van Nieuwenhuysen, E. – PersonEntity: Name: NameFull: Heitz, F. – PersonEntity: Name: NameFull: Wenham, R.M. – PersonEntity: Name: NameFull: Nishio, S. – PersonEntity: Name: NameFull: Lim, M.C. – PersonEntity: Name: NameFull: Marquina, G. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: Apr2026 Type: published Y: 2026 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 37 – Type: issue Value: 4 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
